EP Patent

EP3713590B1 — Human beta 2 defensin for use in the prevention and treatment of graft-versus-host-disease

Assigned to Defensin Therapeutics ApS · Expires 2025-05-07 · 1y expired

What this patent protects

Patent listed against Yorvipath.

Drugs covered by this patent

Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone

Patent Metadata

Patent number: EP3713590B1
Jurisdiction: EP
Classification: —
Expires: 2025-05-07
Drug substance claim: No
Drug product claim: No
Assignee: Defensin Therapeutics ApS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.